NasdaqGS:MYL

Stock Analysis Report

Executive Summary

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally.

Snowflake

Fundamentals

Fair value with moderate growth potential.


Similar Companies

Share Price & News

How has Mylan's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.4%

NasdaqGS:MYL

0.2%

US Pharmaceuticals

1.3%

US Market


1 Year Return

-41.7%

NasdaqGS:MYL

-7.3%

US Pharmaceuticals

2.0%

US Market

MYL underperformed the Pharmaceuticals industry which returned -7.5% over the past year.

MYL underperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

MYLIndustryMarket
7 Day2.4%0.2%1.3%
30 Day17.1%1.2%3.9%
90 Day22.2%-3.6%3.4%
1 Year-41.7%-41.7%-5.0%-7.3%4.2%2.0%
3 Year-47.7%-47.7%12.2%4.4%47.2%37.6%
5 Year-53.4%-53.4%21.1%8.1%60.5%42.9%

Price Volatility Vs. Market

How volatile is Mylan's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mylan undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Mylan's share price is below the future cash flow value, and at a moderate discount (> 20%).

Mylan's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Mylan is overvalued based on earnings compared to the US Pharmaceuticals industry average.

Mylan is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Mylan is poor value based on expected growth next year.


Price Based on Value of Assets

Mylan is good value based on assets compared to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Mylan expected to perform in the next 1 to 3 years based on estimates from 16 analysts?

30.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Mylan's revenue is expected to grow by 2.6% yearly, however this is not considered high growth (20% yearly).

Mylan's earnings are expected to grow significantly at over 20% yearly.

Mylan's revenue growth is positive but not above the United States of America market average.

Mylan's earnings growth is expected to exceed the United States of America market average.

Mylan's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Mylan is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Mylan performed over the past 5 years?

-18.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Mylan's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

Mylan's 1-year earnings growth is negative, it can't be compared to the 5-year average.

Mylan's 1-year earnings growth is negative, it can't be compared to the US Pharmaceuticals industry average.


Return on Equity

Mylan has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Mylan used its assets less efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

Mylan's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Mylan's financial position?


Financial Position Analysis

Mylan is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Mylan's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Mylan's level of debt (111.7%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (245.2% vs 111.7% today).

Debt is not well covered by operating cash flow (14.4%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 3.1x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.5x debt.


Next Steps

Dividend

What is Mylan's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Mylan's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Mylan's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Mylan has not reported any payouts.

Unable to verify if Mylan's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Mylan has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Mylan's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Mylan's salary, the management and board of directors tenure and is there insider trading?

3.7yrs

Average management tenure


CEO

Heather Bresch (50yo)

7.7yrs

Tenure

US$13,332,368

Compensation

Ms. Heather Bresch has been the Chief Executive Officer of Mylan N.V. since January 1, 2012 and its Executive Director since March 01, 2011. Ms. Bresch served as the President of Mylan N.V. from July, 2009 ...


CEO Compensation Analysis

Heather's remuneration is about average for companies of similar size in United States of America.

Heather's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.7yrs

Average Tenure

53yo

Average Age

The tenure for the Mylan management team is about average.


Board Age and Tenure

6.6yrs

Average Tenure

60yo

Average Age

The tenure for the Mylan board of directors is about average.


Insider Trading

More shares have been bought than sold by Mylan individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$353,54819 Aug 19
Melina Higgins
EntityIndividual
Role
Member of the Board of Directors
Independent Non-Executive Director
Shares20,000
Max PriceUS$17.68
BuyUS$642,53915 Aug 19
Sjoerd Vollebregt
EntityIndividual
Shares34,000
Max PriceUS$19.25
BuyUS$1,000,01205 Aug 19
Robert Coury
EntityIndividual
Role
Chairman of the Board
Chairman of The Board
Shares49,859
Max PriceUS$20.06
BuyUS$83,87402 Aug 19
Richard Mark
EntityIndividual
Shares4,000
Max PriceUS$20.97

Ownership Breakdown


Management Team

  • Dennis Zeleny (64yo)

    Chief Human Relations Officer

    • Tenure: 2yrs
  • Rajiv Malik (58yo)

    President & Executive Director

    • Tenure: 6.6yrs
    • Compensation: US$9.51m
  • Heather Bresch (50yo)

    CEO & Executive Director

    • Tenure: 7.7yrs
    • Compensation: US$13.33m
  • Joseph Haggerty

    Corporate Secretary

    • Tenure: 0yrs
  • Dan Gallagher (46yo)

    • Tenure: 0.4yrs
    • Compensation: US$5.28m
  • Ken Parks (56yo)

    Chief Financial Officer

    • Tenure: 3.3yrs
    • Compensation: US$4.41m
  • Tony Mauro (46yo)

    Chief Commercial Officer

    • Tenure: 3.7yrs
    • Compensation: US$4.45m
  • Deb Autor

    Senior VP

    • Tenure: 6.4yrs
  • Melissa Trombetta

    Head of Global Investor Relations

    • Tenure: 0yrs
  • Paul Campbell

    Chief Accounting Officer

    • Tenure: 0yrs

Board Members

  • JoEllen Dillon (55yo)

    Independent Non-Executive Director

    • Tenure: 5.4yrs
    • Compensation: US$405.04k
  • Neil Dimick (70yo)

    Independent Non-Executive Director

    • Tenure: 13.9yrs
    • Compensation: US$391.29k
  • Hal Korman (62yo)

    Non-Executive Director

    • Tenure: 1.3yrs
    • Compensation: US$285.02k
  • Melina Higgins (51yo)

    Independent Non-Executive Director

    • Tenure: 6.6yrs
    • Compensation: US$365.04k
  • Robert Coury (58yo)

    Chairman of The Board

    • Tenure: 3.3yrs
    • Compensation: US$1.80m
  • Pete Vanderveen (68yo)

    Non-Executive Director

    • Tenure: 17.5yrs
    • Compensation: US$335.04k
  • Mark Parrish (63yo)

    Vice Chairman & Lead Independent Director

    • Tenure: 2.1yrs
    • Compensation: US$468.79k
  • Rajiv Malik (58yo)

    President & Executive Director

    • Tenure: 6.6yrs
    • Compensation: US$9.51m
  • Heather Bresch (50yo)

    CEO & Executive Director

    • Tenure: 7.7yrs
    • Compensation: US$13.33m
  • Robert Cindrich (75yo)

    Independent Non-Executive Director

    • Tenure: 8.5yrs
    • Compensation: US$358.79k

Company Information

Mylan N.V.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mylan N.V.
  • Ticker: MYL
  • Exchange: NasdaqGS
  • Founded: 1961
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$11.189b
  • Shares outstanding: 515.87m
  • Website: https://www.mylan.com

Number of Employees


Location

  • Mylan N.V.
  • Building 4
  • Trident Place
  • Hatfield
  • Herefordshire
  • AL10 9UL
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MYLNasdaqGS (Nasdaq Global Select)YesOrdinary SharesUSUSDFeb 1973
6MYDB (Deutsche Boerse AG)YesOrdinary SharesDEEURFeb 1973
0R5PLSE (London Stock Exchange)YesOrdinary SharesGBUSDFeb 1973
MYLWBAG (Wiener Boerse AG)YesOrdinary SharesATEURFeb 1973
MYL NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNFeb 1973

Biography

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North Amer ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/16 00:23
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.